Ab­b­Vie sweeps out ex­per­i­men­tal gas­tro drugs in a post-merg­er pipeline cleanup. And they can like­ly be yours for the right price

Ab­b­Vie nev­er want­ed all the pipeline projects on dis­play at Al­ler­gan. And now the phar­ma gi­ant is writ­ing off an $80 mil­lion in­vest­ment in a mi­cro­bio­me deal as part of its post-merg­er R&D re­vamp.

Al­ler­gan ini­tial­ly plunked down $50 mil­lion to get the col­lab­o­ra­tion on their mi­cro­bio­me gas­troin­testi­nal pro­grams start­ed with As­sem­bly Bio­sciences $ASMB, Mizuho’s Sal­im Syed es­ti­mat­ed that their to­tal spend was around $80 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER